{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-101624","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.408693+00:00","generated_at":"2026-05-17T21:27:07.962951+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Axsome Q2 product revenue $150M (+72% YoY); AUVELITY sales $119.6M","bullets":["Total net product revenue $150.0M, up 72% YoY and 24% sequentially.","AUVELITY net sales $119.6M (+84% YoY); ~192k prescriptions written in Q2.","Net loss narrowed to $48.0M ($0.97/share) from $79.3M ($1.67/share) in Q2 2024.","Cash $303.0M; management says sufficient to fund operations into cash flow positivity.","Pipeline: sNDA for AXS-05 in Alzheimer's agitation on track for Q3 2025; NDA for AXS-12 in narcolepsy expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-101624","json":"https://secwatch.observer/filing/0000950170-25-101624.json","markdown":"https://secwatch.observer/filing/0000950170-25-101624.md","text":"https://secwatch.observer/filing/0000950170-25-101624.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/0000950170-25-101624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:27:07.962951+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}